Table 1 Patients’ demographic and baseline characteristics (n = 13)
Age (years), median (IQR) | 64 (50–68) |
Gender, n (%) | |
 Male | 2 (15.4) |
 Female | 11 (84.6) |
Type of AIT, n (%) | |
 SLIT | 13 (100) |
Target of AIT, n (%) | |
 Cedar pollen | 11 (84.6) |
 Mite | 2 (15.4) |
Concomitant asthma, n (%) | 1 (7.7) |
Concomitant RADs, n (%) | |
 RA | 8 (61.5) |
 Other RADs | 5 (38.5) |
Disease duration of RADs (year), median (IQR) | 7.6 (6.7–10.5) |
Positive for anti-CCP antibodies, a n (%) | 5 (62.5) |
Positive for rheumatoid factor, a n (%) | 6 (75) |
Glucocorticoid use, n (%) | 3 (23) |
 Dose(mg/day), b median (IQR) | 1 (0.88–2.5) |
Methotrexate use, n (%) | 4 (30.7) |
 Dose(mg/day), b median (IQR) | 6 (5.75–6.5) |
Other immunosuppressants use, n (%) | 2 (15.3) |
Immunomodulators use, n (%) | 2 (15.3) |
Biologics use, n (%) | 6 (46.1) |